Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) lacks the antitachycardia pacing (ATP) capability of tranvenous ICDs (TV-ICD). S-ICD patient selection can be challenging as some patients may benefit from ATP. We aim to identify clinical predictors of ATP benefit, in order to improve patient selection for S-ICD or TV-ICD therapy.
Methods: De novo single- and dual-chamber TV-ICD patients implanted between March 2011 and December 2015 were included. Ventricular arrhythmias terminated by ATP and not followed by a shock were considered successful ATP therapy. Cox proportional hazard analysis was performed to assess the adjusted effect of multiple predictors for appropriate ATP and shock therapy.
Results: Note that 431 patients were included with a median follow-up of 26 months. Ninety-nine patients (23%) received appropriate ATP therapy, which terminated the arrhythmia in 67%. A history of nonsustained ventricular tachycardia (NSVT) or monomorphic VT (MVT) was the only predictor of appropriate ATP therapy in the multivariable model (hazard ratio [HR] 2.73, P < 0.001). Sixty-five of 221 patients with a history of NS (VT) received appropriate ATP (29%) versus 24 patients (11%) without a history NS (VT) (P < 0.001). A secondary prevention indication was the only predictor in the multivariate model for appropriate shock therapy (HR 1.82, P = 0.05).
Conclusion: A history of NSVT or MVT is a significant predictor for appropriate and successful ATP therapy. One in three patients with NSVT or MVT received appropriate ATP versus one in 10 patients without a history of NSVT or MVT over a 2-year period of follow-up.
Keywords: antitachycardia pacing; appropriate ICD therapy; implantable cardioverter-defibrillator; inappropriate ICD therapy; patient selection; subcutaneous ICD; transvenous ICD.
© 2018 Wiley Periodicals, Inc.